Loading stock data…
BHC
$5.65-0.07 (-1.22%)
Market ClosedLast close May 1
Bausch Health Companies Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bausch Health Companies Inc. in the Healthcare sector is trading at $5.65. The stock is currently 35% below its 52-week high of $8.69, remaining 11.3% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why BHC maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.65
Potential Upside
9.6%
Whystock Fair Value$6.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$7.57+34.0%
Range$6.00 – $9.00
Fundamentals
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.07B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.19
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.69%
Volume
Today's trading volume
3.08M
Recent News
Why Bausch Health Companies Was Crawling Higher This Week
Investors liked what they saw with the company's opening 2026 earnings report.
TSX up 455 Points at Midday With Healthcare, Materials, The Best Performers
The Toronto Stock Exchange is up 455 points at midday, partially recouping some of the 630 points lo
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
Bausch Health Companies Inc (BHC) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Bausch Health Companies Inc (BHC) reports a robust 14% revenue increase, driven by Salix and Solta, while navigating challenges in its diversified segment.
Bausch + Lomb Q1 Earnings Call Highlights
Bausch + Lomb (NYSE:BLCO) reported first-quarter 2026 results that management said show improving earnings quality and operating leverage alongside steady revenue growth, driven by strength in pharmaceuticals and continued momentum in vision care. Management emphasizes “quality of growth” and opera